First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer
Maria Vittoria Dieci(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Laura Merlini(Azienda Ospedale - Università Padova), Giorgio Bonciarelli, Valentina Guarneri(Istituto Oncologico Veneto), Felice Pasini(Ospedale Civile Di Ivrea), Cristina Oliani(Ospedale Maggiore), Silvia Michieletto(Istituto Oncologico Veneto), Giampaolo Tortora(University of Naples Federico II), Tommaso Giarratano(Istituto Oncologico Veneto), Enrico Orvieto(AULSS 2 Marca Trevigiana), Marta Mion(University of Padua), Paola Del Bianco(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Costanza De Rossi(Ospedale dell' Angelo), Gian Luca De Salvo(Istituto Oncologico Veneto)
Cited by 13
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830